guest ::
| Home > Publications database > Diabetes mellitus in long-term survivors with colorectal, breast, or prostate cancer: Prevalence and prognosis. A population-based study. > print |
| Home > Publications database > Diabetes mellitus in long-term survivors with colorectal, breast, or prostate cancer: Prevalence and prognosis. A population-based study. > print |
| 001 | 285584 | ||
| 005 | 20240423094335.0 | ||
| 024 | 7 | _ | |a pmid:37996981 |2 pmid |
| 024 | 7 | _ | |a 1934-662X |2 ISSN |
| 024 | 7 | _ | |a 0008-543X |2 ISSN |
| 024 | 7 | _ | |a 1045-7410 |2 ISSN |
| 024 | 7 | _ | |a 1097-0142 |2 ISSN |
| 024 | 7 | _ | |a 1934-6638 |2 ISSN |
| 024 | 7 | _ | |a DOI:10.1002/cncr.35133 |2 doi |
| 024 | 7 | _ | |a DOI:10.1002/cncr.35133 |2 doi |
| 024 | 7 | _ | |a altmetric:156872584 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-02446 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Yang, Keyi |0 P:(DE-He78)16bd6dc077b72d72e810fd10afeadb09 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Diabetes mellitus in long-term survivors with colorectal, breast, or prostate cancer: Prevalence and prognosis. A population-based study. |
| 260 | _ | _ | |a New York, NY |c 2024 |b Wiley-Liss |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1713858162_12989 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:C071#LA:C071# / 2024 Apr 1;130(7):1158-1170 |
| 520 | _ | _ | |a Patients with cancer are at increased risk of diabetes mellitus (DM). Previous studies on the prevalence and prognostic impact of DM in cancer survivors were limited by small sample sizes or short follow-up times. We aimed to compare the patient-reported prevalence of DM in long-term cancer survivors (LTCS), who survived 5 years or more after cancer diagnosis, with that in cancer-free controls, and to estimate the mortality risk among LTCS according to DM status.Our population-based cohort comprised 6952 LTCS diagnosed with breast, colorectal, or prostate cancer between 1994 and 2004, recruited in 2008-2011 (baseline), and followed until 2019. A total of 1828 cancer-free individuals served as controls. Multivariable logistic regression was used to compare the prevalence of DM in LTCS and controls, and according to covariates at baseline. Mortality among LTCS according to DM was assessed by Cox proportional hazards regression.A total of 962 (13.8%) LTCS at baseline reported DM. Prevalence of DM in LTCS was not higher than in cancer-free controls, both at baseline (odds ratio, 0.80; 95% CI, 0.66-0.97) and at follow-up (odds ratio, 0.83; 95% CI, 0.67-1.04). Prevalence of DM in LTCS was associated with cancer site, older age, lower education, higher socioeconomic deprivation, higher body mass index, physical inactivity, other comorbidities, and poorer prognosis (adjusted hazard ratio [all-cause mortality] = 1.29; 95% CI, 1.15-1.44).DM in LTCS is prevalent, but not higher than in cancer-free population controls. Cancer survivors with concurrent DM are at a potentially higher risk of death.Cancer and diabetes mellitus (DM) are two serious threats to global health. In our study, prevalence of DM in long-term cancer survivors who survived 5 years or more after cancer diagnosis was not higher than in cancer-free controls. This should not be interpreted as an indication of a lower risk of DM in cancer survivors. Rather, it highlights the potentially poor prognosis in diabetic cancer survivors. Therefore, keeping a continuous satisfactory DM and hyperglycemia management is essential during long-term cancer survivorship. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a cancer survivors |2 Other |
| 650 | _ | 7 | |a control group |2 Other |
| 650 | _ | 7 | |a diabetes mellitus |2 Other |
| 650 | _ | 7 | |a mortality |2 Other |
| 650 | _ | 7 | |a prevalence |2 Other |
| 700 | 1 | _ | |a Doege, Daniela |0 P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b |b 1 |u dkfz |
| 700 | 1 | _ | |a Thong, Melissa S Y |0 P:(DE-He78)24fe6057396bec79d2638615b12eb989 |b 2 |u dkfz |
| 700 | 1 | _ | |a Koch-Gallenkamp, Lena |0 P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88 |b 3 |u dkfz |
| 700 | 1 | _ | |a Weisser, Linda |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Bertram, Heike |b 5 |
| 700 | 1 | _ | |a Eberle, Andrea |b 6 |
| 700 | 1 | _ | |a Holleczek, Bernd |b 7 |
| 700 | 1 | _ | |a Nennecke, Alice |b 8 |
| 700 | 1 | _ | |a Waldmann, Annika |b 9 |
| 700 | 1 | _ | |a Zeissig, Sylke Ruth |b 10 |
| 700 | 1 | _ | |a Pritzkuleit, Ron |b 11 |
| 700 | 1 | _ | |a Jansen, Lina |0 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09 |b 12 |u dkfz |
| 700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 13 |u dkfz |
| 700 | 1 | _ | |a Arndt, Volker |0 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0 |b 14 |e Last author |u dkfz |
| 773 | _ | _ | |a DOI:10.1002/cncr.35133 |0 PERI:(DE-600)1479932-7 |n 7 |p 1158-1170 |t Cancer |v 130 |y 2024 |x 0008-543X |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:285584 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)16bd6dc077b72d72e810fd10afeadb09 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)24fe6057396bec79d2638615b12eb989 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER-AM CANCER SOC : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCER-AM CANCER SOC : 2022 |d 2023-10-21 |
| 920 | 2 | _ | |0 I:(DE-He78)C071-20160331 |k C071 |l C071 Cancer Survivorship |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C071-20160331 |k C071 |l C071 Cancer Survivorship |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 3 |
| 920 | 0 | _ | |0 I:(DE-He78)C071-20160331 |k C071 |l C071 Cancer Survivorship |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C071-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|